Karen Sisley

Dr. Karen Sisley

Weston Park Cancer Centre, Department of Oncology & Metabolism, University of Sheffield, Sheffield, S10 2RX and Sheffield Ocular Oncology Service, Royal Hallamshire Hosptial, UK
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1997 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
KSKaren Sisley
Karen Sisley
IRIan G. Rennie
Ian G. Rennie
MPM. Andrew Parsons
M. Andrew Parsons
RJRhona Jacques
Rhona Jacques
DHDavid W. Hammond
David W. Hammond
RRRobert C. Rees
Robert C. Rees

1 September 1990 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
KSKaren Sisley
Karen Sisley
IRIan G. Rennie
Ian G. Rennie
DCDavid W. Cottam
David W. Cottam
APAnthony M. Potter
Anthony M. Potter
CPChristopher W. Potter
Christopher W. Potter
RRRobert C. Rees
Robert C. Rees

1 October 1992 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
KSKaren Sisley
Karen Sisley
DCDavid W. Cottam
David W. Cottam
IRIan G. Rennie
Ian G. Rennie
MPM. Andrew Parsons
M. Andrew Parsons
APAnthony M. Potter
Anthony M. Potter
RRRobert C. Rees
Robert C. Rees

1 December 2001 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
KPK A Patel
K A Patel
KSKaren Sisley
Karen Sisley
NEN D Edmondson
N D Edmondson
FTF Talbot
F Talbot
MPM A Parsons
M A Parsons
KSK Sisley
K Sisley
Background/aims: Liquid nitrogen spray freezing has been successfully applied for basal cell carcinomas in the eyelid region, but is not yet in general use. The reasons for this were analysed and the development of a more reliable, safer cryosurgical technique aimed for. Methods: New cryosurgical apparatus, contact probes with increased freezing power, and a special application technique were developed and clinically tested in a consecutive series of 221 patients with primary basal cell carcinomas of the lid region. Special efforts yielded follow up reports of 220 out of the 221 patients. Results: Experimental measurements and clinical results demonstrated that this cryosurgical technique was at least as effective as spray freezing, with lower risks. The rate of recurrent tumours in patients followed up for 5 years or longer was 5.1% (surgeons first result) respectively 0.6% (result after optimised second cryosurgery). The figures were 6.8%, respectively max 2.7%, when including all patients, independent of follow up time. Conclusion: Traditional surgery and histopathology, still used at numerous places, resulted in higher recurrence rates despite extended loss of healthy eyelid tissues and should be abandoned. Micrographic surgery is considered mandatory to save more of the healthy structures and to obtain lower recurrence rates. Cost and time require worldwide restriction of micrographic surgery to selected cases. Updated cryosurgery provides a low cost option to micrographic surgery and results in preservation of eyelid structures and lacrimal pathways, tarsal plate, lid margin. It provides excellent cosmetic results. Thus, primary basal cell carcinomas in the eyelid region of suitable size and location should receive updated cryosurgery, and tumours beyond its range micrographic surgery.

1 January 2000 in British Journal of Cancer
Verified
Journal Article
Open access
KSKaren Sisley
Karen Sisley
MPM A Parsons
M A Parsons
JGJ Garnham
J Garnham
APA M Potter
A M Potter
DCD Curtis
D Curtis
IRI G Rennie
I G Rennie
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

1 June 2018 in Ophthalmology
Verified
Journal Article
Open access
NPNatasha M. van Poppelen
Natasha M. van Poppelen
JVJolanda Vaarwater
Jolanda Vaarwater
HMHardeep S. Mudhar
Hardeep S. Mudhar
KSKaren Sisley
Karen Sisley
IRIan G. Rennie
Ian G. Rennie
RVRobert M. Verdijk
Robert M. Verdijk
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Iris melanoma comprises 4% to 10% of all UMs and has a lower mortality rate. The genetic changes in iris melanoma are not as well characterized as ciliary body or choroidal melanoma. The aim of this study was to gain more insight into the genetic background of iris melanoma and iris nevi. Multicenter, retrospective case series. Patients diagnosed with iris melanoma or iris nevi who underwent surgical intervention as primary or secondary treatment. Next-generation sequencing of GNAQ, GNA11, EIF1AX, SF3B1, BAP1, NRAS, BRAF, PTEN, c-Kit, TP53, and TERT was performed on 30 iris melanomas and 7 iris nevi. Copy number status was detected using single nucleotide polymorphisms (SNPs) included in the next-generation sequencing (NGS) panel, SNP array, or fluorescent in situ hybridization. BAP1 immunohistochemistry was performed on all samples. Mutation and copy number status were analyzed. Results of BAP1 immunohistochemistry were used for survival analysis. In 26 of the 30 iris melanoma and all iris nevi, at least 1 mutation was identified. Multiple mutations were detected in 23 iris melanoma and 5 nevi, as well as mutations in GNAQ and GNA11. Furthermore, 13 of 30 BAP1, 5 of 30 EIF1AX, and 2 of 30 SF3B1 mutations were identified in iris melanoma. No correlation between BAP1 status and disease-free survival was found. The iris nevi showed 1 EIF1AX and 3 BAP1 mutations. Two of the nevi, with a BAP1 mutation, were histologically borderline malignant. Mutations in NRAS, BRAF, PTEN, c-KIT, and TP53 were detected in 6 iris melanomas and 4 iris nevi. Mutations that are often found in uveal and cutaneous melanoma were identified in this cohort of iris melanomas and iris nevi. Therefore, iris melanomas harbor a molecular profile comparable to both choroidal melanoma and cutaneous melanoma. These findings may offer adjuvant targeted therapies for iris melanoma. There was no prognostic significance of BAP1 expression as seen in choroidal melanoma. Consequently, iris melanoma is a distinct molecular subgroup of UM. Histologic borderline malignant iris nevi can harbor BAP1 mutations and may be designated iris melanocytic tumors of uncertain malignant potential.